MRES:
Institute of
Biomedical Research Announces Application for Name Change
and
New Ticker Symbol
in Anticipation of Future M&A Activities and Senior
Listing
CAPE TOWN,
SOUTH AFRICA -- July 5, 2023 -- InvestorsHub NewsWire
-- Institute of Biomedical Research Corp. (OTC
PINK: MRES) ("Institute of Biomedical Research" or the
"Company"), a nutraceutical biotechnology company focused on
alternative plant-based cannabinoids, medical psilocybin and mental
health therapeutic research powered by artificial intelligence, and
evidence-based sustainable products and solutions, is pleased to
share the following update and corporate
initiatives:
The Company
has instructed its corporate lawyer of record,
Matthew McMurdo, Esq.
of
McMurdo Law Group, LLC, New York, New York to start the process of
Corporate Name Change and New Ticker Symbol, and to take all
measures immediately to effectuate such.
MRES intends to undergo a name change that better reflects the
company's evolving business objectives and strategic direction. The
new name will capture the essence of MRES's expansion plans and
reinforce its commitment to delivering innovative solutions and
sustainable growth in the biotechnology sector. Furthermore, MRES
will adopt a new ticker symbol to coincide with its name
change.
Jeff Robinson, CEO of
Institute of Biomedical Research,
expressed optimism about the future and the opportunities that lie
ahead. "We are excited to embark on this transformative journey,
which we believe will position MRES as a formidable player in the
biotechnology and phytomedicine sector. The name change and new
ticker symbol will align our corporate business objectives and
strategic direction with M2Bio and its related brands and assets.
As well, these initiatives will enable us to explore strategic
M&A opportunities and aim for a senior listing which will
benefit our shareholders and further our growth trajectory. This is
extremely exciting for us and I am beyond ecstatic! Stay tuned and
keep connecting the dots.''
MRES will keep its shareholders and the investment community
informed of the progress related to the name change and new ticker
symbol. Updates will be shared through press releases, regulatory
filings, the company's official website and social media
accounts.
About Institute of
Biomedical Research Corp./ DBA M2Bio Sciences
Institute of Biomedical Research
Corp, is a nutraceutical biotechnology company focused on
alternative plant-based cannabinoids, medical psilocybin and mental
health therapeutic research powered by artificial intelligence, and
evidence-based sustainable products and solutions, that develops
and commercializes a range of CBD and mushrooms-based products
under Dr. AnnaRx™, Medspresso™, Liviana™ brands as well as
artificial intelligence powered nutrition products and solutions
under the M2Biome brand. In addition, our research and clinical
trials with psilocybin are aimed at new therapies that will help
patients who suffer from alcohol addiction, mental illness, and
cardiovascular diseases. Our mission is to advance botanical-based
medicine to the forefront by deploying best-practice science and
medicine, clinical research, and emerging technologies such as
artificial intelligence. The Company is traded on the
Over-the-Counter Bulletin Board of NASDAQ under the trading symbol
"MRES".
Publicly traded Company (OTC
Pink: MRES)
www.m2bio.co
jeff@m2bio.co
+27 72 333 2148
Find M2Bio™ on
social media
Facebook:
M2Bio
Instagram:
M2bio.Sciences
LinkedIn:
M2Bio
Twitter:
@M2bio
Forward-Looking
Statements
Safe Harbour
Statement - In addition to historical information, this press
release may contain statements that constitute forward-looking
statements within the meaning of the Securities Act of 1933 and the
Securities Exchange Act of 1934, as amended by the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements contained in this press release include the intent,
belief, or expectations of the Company and members of its
management team with respect to the Company's future business
operations and the assumptions upon which such statements are
based. Prospective investors are cautioned that any such
forward-looking statements are not guarantees of future
performance, involve risks and uncertainties and that actual
results may differ materially from those contemplated by such
forward-looking statements. Factors that could cause these
differences to include, but are not limited to, failure to complete
anticipated sales under negotiations, lack of revenue growth,
client discontinuances, failure to realize improvements in
performance, efficiency, and profitability, and adverse
developments with respect to litigation or increased litigation
costs, the operation or performance of the Company's business units
or the market price of its common stock. Additional factors that
could cause actual results to differ materially from those
contemplated within this press release can also be found on the
Company's website. The Company disclaims any responsibility to
update any forward-looking statements. mres